Skip to content

Low Dose Aspirin Alerts in High-Risk Pregnancies

Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05802940
Enrollment
830
Registered
2023-04-07
Start date
2023-06-19
Completion date
2026-01-27
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin, Clinical Decision Support Systems, Economics, Behavioral, Preeclampsia

Brief summary

The goal of this study is to assess the effect of an electronic health record (EHR) clinical decision support tool, also known as a best practice alert (BPA), on healthcare provider recommendations for low dose aspirin use in a high-risk pregnant patient population. The investigators hypothesize that the implementation of the EHR BPA tool will increase the healthcare provider's recommendation for low dose aspirin compared to current standard care.

Detailed description

Low dose aspirin (LDA) has been found to reduce the incidence of preeclampsia in high-risk pregnant patients. At a health system serving central and northeastern Pennsylvania, electronic health record data reveal that clinicians recommend an LDA regimen to only 60% of eligible high-risk pregnant patients, suggesting the need and opportunity for increased LDA recommendation. This study will assess the efficacy of an electronic health record based clinician-facing interruptive clinical decision support tool/best practice alert (BPA) aimed at increasing LDA recommendation for pregnant patients who are at high risk of preeclampsia. Up to 704 patients will be randomized to account for possible 10% miscarriage and early termination rate as we require outcome data on a total of 640 patients for adequate power. Eligible patients will be randomized to a control group, where the clinician receives no BPA, and one experimental group, where the provider receives a BPA noting the patient is at high-risk and recommend the provider order LDA. If LDA is not recommended, there will be a required acknowledgment reason from the provider noting a rationale for not initiating a LDA regimen.

Interventions

BEHAVIORALElectronic health record best practice alert

The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.

Sponsors

Geisinger Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

We will randomize at level of the patient as to whether or not a BPA will fire when the patient is seen in clinic. Any obstetric care provider who sees a patient that has been randomized to BPA group will receive the alert if indicated. If the alert doesn't fire, the care provider will not be aware as to whether the patient is randomized to the BPA group or whether the alert was not indicated. Clinical investigators and outcomes assessors are blinded.

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Receiving prenatal care within Geisinger * Initial prenatal visit prior to 28 weeks gestation * Determined to be high risk for preeclampsia based on the modified United States Preventive Services Task Force and American College of Obstetrics and Gynecology criteria (at least 1 high risk factor)

Exclusion criteria

* Not pregnant * No prenatal visit prior to 28 weeks gestation * Maternal-Fetal Medicine only visits * Not meeting the modified USPSTF high-risk criteria * Contraindication to aspirin, including allergy

Design outcomes

Primary

MeasureTime frameDescription
A sensitivity analysis of the healthcare provider recommendation for low dose aspirin use in patients, specifically those who deliver after 28 weeksAssessed between initial prenatal visit and delivery after 28 weeksyes/no

Secondary

MeasureTime frameDescription
The healthcare provider recommendation for low dose aspirin use in all randomized patientsAssessed between initial prenatal visit and deliveryyes/no

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORA. Dhanya Mackeen, MD, MPH

Geisinger Clinic

PRINCIPAL_INVESTIGATORAmir Goren, PhD

Geisinger Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026